Endocrine profile and therapeutic employment of a new prolactin-lowering drug, metergoline.
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000568:Amenorrhea / Q000188:drug therapy; D001786:Blood Glucose / Q000378:metabolism; D003480:Cushing Syndrome / Q000188:drug therapy; D007172:Erectile Dysfunction / Q000188:drug therapy; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006062:Gonadotropins / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D007774:Lactation / Q000187:drug effects; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008711:Metergoline / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D010187:Pancreatic Hormones / Q000378:metabolism; D010868:Pimozide / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D011954:Receptors, Dopamine / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013972:Thyrotropin / Q000378:metabolism
D001786:Blood Glucose; D004873:Ergolines; D006062:Gonadotropins; D006728:Hormones; D010187:Pancreatic Hormones; D011954:Receptors, Dopamine; D012702:Serotonin Antagonists; D008711:Metergoline; D010868:Pimozide; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D013972:Thyrotropin; D013006:Growth Hormone